UK-based Shire Pharmaceuticals is selling a block of medicines to Almirall [1]Â of Spain for $213 million. The remedies--deemed "non-core products"--include two skin treatments, Solaraze and Vaniqa. Company officials say the move will let Shire focus on its core therapeutic areas: attention deficit disorder, gastrointestinal and renal disease, and genetic therapies.
The company also wants to expand its international reach and develop a new specialty in regenerative medicine. Recently Shire licensed the anti-scarring remedy Juvista from Renovo, in its first foray into the regenerative arena.
- see the release [2] from Shire
- check out this article [3] for more
Related Articles:
Shire to Massachusetts: Pass incentive bill now. Report [4]
FDA signals a quick approval for Shire's ADHD drug. Report [5]
Shire snares New River Pharma in $2.6B buyout. Report [6]
Shire gambit aimed at delaying generic Adderall XR. Report [7]
Links:
[1] http://www.fiercebiotech.com/story/almirall-gw-pharma-ink-deal-for-cannabis-based-sativex/2005-12-12
[2] http://www.fiercebiotech.com/press-releases/press-release-shire-pharmaceuticals-group-sells-medicines-almirall-prodesfarma-213-mi
[3] http://news.bbc.co.uk/2/hi/business/7033285.stm
[4] http://www.fiercebiotech.com/story/shire-massachusetts-pass-incentive-bill-now/2007-08-31
[5] http://www.fiercebiotech.com/story/fda-signals-a-quick-approval-for-shire-s-adhd-drug/2007-06-21
[6] http://www.fiercebiotech.com/story/shire-snares-new-river-pharma-in-2.6b-buyout/2007-02-20
[7] http://www.fiercebiotech.com/story/shire-gambit-aimed-at-delaying-generic-adderall-xr/2005-10-13